arrow_back Back to App

Enhancing Drug Production: Centers of Excellence for Secure Medicine Supply

This act aims to improve the security of drug supply in the United States by supporting modern pharmaceutical manufacturing methods. This will make medicines more accessible and of higher quality, directly impacting citizens' health and safety. The creation of specialized research centers is intended to foster innovation and train future professionals in this field.
Key points
Establishes "National Centers of Excellence" in advanced and continuous pharmaceutical manufacturing to conduct research and development.
These centers will collaborate with drug manufacturers and government agencies to implement new technologies and train the workforce.
The goal is to reduce reliance on foreign suppliers and enable faster responses to drug shortages or health threats like pandemics.
Funding of $80 million is authorized for fiscal years 2022-2026 to support these centers.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_2589
Sponsor: Sen. Blackburn, Marsha [R-TN]
Process start date: 2021-08-03
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Securing America’s Medicine Cabinet Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_2589.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-08-03.

What are the main provisions?

Key points include:

  • Establishes "National Centers of Excellence" in advanced and continuous pharmaceutical manufacturing to conduct research and development.
  • These centers will collaborate with drug manufacturers and government agencies to implement new technologies and train the workforce.
  • The goal is to reduce reliance on foreign suppliers and enable faster responses to drug shortages or health threats like pandemics.
  • Funding of $80 million is authorized for fiscal years 2022-2026 to support these centers.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Blackburn, Marsha [R-TN].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-01-02.

CATEGORIES

Health Public Investments